Severity assessment by the CRB-65 score used to determine the management of community-acquired pneumonia in patients in the community.1
Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJM. Predicting Death in Elderly Patients With Community-Acquired Pneumonia: A Prospective Validation Study Reevaluating the CRB-65 Severity Assessment Tool. Arch Intern Med. 2008;168(13):1465-1468. doi:10.1001/archinte.168.13.1465
Severity scores are helpful in predicting mortality in patients presenting with community-acquired pneumonia (CAP). They enable physicians to decide their management strategies and site of care according to the expected mortality risk. In Europe, most cases of lower respiratory tract infections (LRTIs) and CAP are managed in primary care settings by general practitioners (GPs). However, most severity scores have been derived and validated in a hospital setting.
The best accepted tools to discriminate patients with CAP into high or low risk are the CURB-65 score (confusion, serum urea nitrogen level >19.6 mg/dL [to convert to millimoles per liter, multiply by 0.357], respiratory rate ≥30/min, low blood pressure, and age ≥65 years) and the Pneumonia Severity Index (PSI).1,2 The CURB-65 score consists of 5 easily accessible data, while the PSI includes many tests that are not accessible in primary care. This latter score is therefore not useful for the GP. Recently, several studies evaluated the CURB-65 score and confirmed its validity, but validation was not yet done in an unselected primary care population.3- 9
A modification of the CURB-65 score, the CRB-65 score, is recommended by GPs in the communities where serum urea nitrogen measurements are often unavailable. It is expected to support GP judgment in stratifying patients into different management groups, ranging from home treatment to urgent hospital admission (Figure).1 This management model seems unlikely to be practical in a primary care population because it recommends hospital referral for a score of 1 or higher and thus for all patients older than 65 years (Figure). We therefore conducted a study to evaluate the validity of the CRB-65 score in primary care.
Between November 2005 and May 2006, Dutch GPs prospectively included patients with CAP who were 65 years or older. Community-acquired pneumonia was diagnosed on the basis of the presence of 1 or more features, including new localizing signs present during chest examination, new infiltrates on a chest radiograph, or when the GP had a strong suspicion of the patient having CAP because of severe dyspnea in a very ill patient, even in the absence of chest signs. This third criterion for CAP was chosen because it equates to usual practice in daily primary care, thus ensuring the generalizability of study results.
Patients were not included in the study if they were known to have lung cancer, a hematologic malignant neoplasm, or an infection with the human immunodeficiency virus; used immunosuppressive medication (except prednisone); had been hospitalized during the 2 weeks preceding the diagnosis; or were nursing home residents.
Data, including all CRB items and age, were collected prospectively at the same time as the index consultation, when diagnosis and management was decided. The CRB-65 rule is scored on the presence of the following: confusion, respiratory rate 30/min or higher, low blood pressure (systolic blood pressure <90 or diastolic blood pressure ≤60 mm Hg), and age 65 years or older. The main outcome measure was 30-day mortality.
Descriptive statistics included frequencies, percentages, and means. We examined the accuracy of the CRB-65 rule in episodes of CAP using SPSS version 12.1 for Windows (SPSS Inc, Chicago, Illinois), with 30-day mortality as the outcome. Positive predictive value, negative predictive value), sensitivity, specificity, and the area under the receiver operating characteristic curve with corresponding 95% confidence intervals (CIs) were calculated and compared with the original study of Lim et al.1 Next, the mortality for different CRB-65 scores was determined. We also calculated the correlation between the individual CRB-65 scores and referral patterns.
The study population comprised 315 elderly patients (mean age, 77.3 years) who lived at home and were diagnosed as having CAP. Of these, the diagnosis for 17 patients was only on the basis of a strong suspicion of having pneumonia (third diagnostic criterion). In 119 patients, a chest radiograph was present, with 50 showing infiltrates. One patient was lost to follow-up and was excluded from the analysis. Forty-seven patients (15%) were hospitalized and 11 (3.5%) died within 30 days (Table 1). Mortality was 4% in patients with a chest radiograph. Of the patients, 89% were treated initially by the GP with antibiotics, 7% were referred to hospital immediately, and 4% did not receive antimicrobial treatment nor were they referred immediately (none of these 14 patients died within 30 days).
By comparison with the original study by Lim et al,1 a similar trend was found in the association between the CRB-65 score and 30-day mortality, although none of our patients had a score of 0 (since they were all 65 years or older) or a high score of 4 (Table 2). The test characteristics of the CRB-65 score in our study, taking a cutoff score of 2 or higher, were very much similar to that of the original cohort (Table 3). Also, the discriminative value was good (area under receive operating characteristic curve, 0.79; 95% CI, 0.65-0.92).
Patients with a score of 1 (73%) had a low mortality rate of 0.9%, suggesting that they may be suitable for usual home management. A score of 2 or higher was associated with a much higher mortality rate (11%), suggesting patients required either close monitoring at home or hospital referral (Table 2). This is not in agreement with the site of care decision recommended in the British Thoracic Society guidelines10,11 and the study by Lim et al1 (Figure).
In our study cohort, only 23 patients (7.3%) with pneumonia were referred to the hospital. Of the 230 patients with a score of 1, only 9 were referred to the hospital and the remainder were treated at home. Two patients (0.9%) died, both in the home-managed group. Only 7 patients with a CRB-65 score of 3 were referred to the hospital, and of the other 16 patients treated at home, 2 (13%) died (Table 4).
When using a score of 2 or higher to indicate high risk, our study showed that the CRB-65 score has similar accuracy in predicting 30-day mortality in elderly primary care patients compared with the original study of Lim et al1 including patients of all ages in a hospital setting. Thus, our study shows that in an elderly primary care population, the cutoff for considering hospital referral can be increased to a score of 2 or higher. This does not imply that all such patients should be referred to a hospital. Referral also depends on other adverse prognostic features, social circumstances, and wishes of the patient, as well as the availability of close health monitoring at home. Whether referral to a hospital will decrease mortality rates in high-risk patients with CAP is even not entirely clear. In our study, most patients with an elevated risk were not referred. Whether the mortality rate would be lower if they would have been sent to a hospital is unknown.
The results from this study differ somewhat from other validation studies. In particular, the a priori probability of 30-day mortality was lower than in previous validation studies (3.5% vs 4.3% to 14%).1,3- 6,8,12 In these earlier studies, however, mixed groups of referred and nonreferred patients with probably a higher risk for complications were studied. Another possible explanation for the low mortality could be that bacterial resistance rates are low in the Netherlands. However, overall Dutch mortality rates for CAP are not lower compared with those in countries with higher resistance rates.13
Discrimination between different kinds of LRTI is difficult in primary care because pulmonary radiography and laboratory tests are not routinely carried out. We chose to include CAP without radiographic evidence to follow daily GP practice more accurately. Although it seems that differentiation between CAP and acute bronchitis is more difficult without radiography, the prognosis of these 2 forms of LRTI was very different in our whole study, with a mortality rate of 3.5% in patients with CAP and 0.2% for those with acute bronchitis. Because death in acute bronchitis was very infrequent, using the CRB-65 score as a predictor of 30-day mortality in acute bronchitis was not useful. New studies should focus on predicting other unfavorable outcomes, apart from death, in a broader range of LRTIs.
In conclusion, the simple CRB-65 severity assessment tool accurately identifies low-risk patients in an elderly primary care population and suggests that age alone is not a sufficient reason to classify patients as high risk. Patients with a score of 2 or higher have an increased risk and should be intensively monitored, for example, by reconsultation within 24 to 48 hours or should be referred to secondary care. Because mortality rates are low in primary care, new studies should focus on less severe outcomes.
Correspondence: Dr Bont, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, PO Box 85060, 3508 AB Utrecht, the Netherlands (email@example.com).
Author Contributions: Dr Bont had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Bont, Hak, Hoes, and Verheij. Acquisition of data: Bont and Verheij. Analysis and interpretation of data: Bont, Hak, Hoes, Macfarlane, and Verheij. Drafting of the manuscript: Bont, Hak, and Verheij. Critical revision of the manuscript for important intellectual content: Hoes, Macfarlane, and Verheij. Statistical analysis: Bont, Hak, and Hoes. Obtained funding: Hoes and Verheij. Administrative, technical, and material support: Bont, Verheij. Study supervision: Hak, Hoes, and Verheij.
Financial Disclosure: None reported.
Funding/Support: This study was funded through a personal grant by the Netherlands Scientific Organization to Dr Bont (AGIKO [Assistent Geneeskundige in Opleiding tot Klinisch Onderzoeker] No. 920-03-254). The research database of the University Medical Center Utrecht primary care network is funded by the UMC Utrecht.